dr. jonathan r. strosberg on 177-lu-dotatate in patients with neuroendocrine tumors
Published 8 years ago • 2.3K plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:19
dr. strosberg on future of 177lu-dotatate therapy in neuroendocrine tumors
-
1:03
dr. strosberg on retreatment with 177lu-dotatate in advanced nets
-
1:59
netter-1 update: 177lu-dotatate in patients with midgut neuroendocrine tumors
-
1:14
dr. strosberg on pasireotide for neuroendocrine tumors
-
2:16
dr. strosberg on quality of life findings for lu-dotatate in patients with midgut nets
-
1:38
dr. strosberg on challenges in the treatment of neuroendocrine tumors
-
2:08
dr. strosberg discusses trials in neuroendocrine tumors
-
35:25
neuroendocrine cancer - common diet myths
-
18:16
surgery for neuroendocrine tumors
-
6:41
net patient story: re-treatment with prrt (salvage prrt)
-
1:25
dr. jonathan r. strosberg on the netter-1 trial and its impact on patients with midgut nets
-
0:49
dr. strosberg on fda approval of lutathera for gep-nets
-
1:14
dr. strosberg on radiolabeled somatostatin analogs in gep-nets
-
2:03
dr. strosberg on the results of the netter-1 trial
-
1:57
177lu-dotatate in patients with well-differentiated, high-grade nets
-
6:59
recently approved drugs: lutetium lu 177 dotatate for treatment of gep-nets
-
3:09
new treatment for neuroendocrine tumors
-
4:20
limitations in the management of nets
-
7:00
treating metastases associated with neuroendocrine tumors (nets)
-
2:58
netter-1: radioactive octreotide effective in metastatic neuroendocrine tumors
-
2:34
lutathera therapy: targeted internal radiation
-
8:08
prrt sequencing and the future of neuroendocrine tumor treatments with jonathan strosberg, md